Vora GK, Demirci H, Marr B, Mruthyunjaya P. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2017;62:26–42.

Article  PubMed  Google Scholar 

Hu D-N, Yu G, McCormick SA, Finger PT. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol. 2008;145:418–23.

Article  PubMed  Google Scholar 

Kanaeko T. Frequency of ocular malignant melanoma in Japan. Rinsho Ganka. 1979;33:941–7. (in Japanese).

Google Scholar 

Matsumoto A, Inatomi T, Kinoshita S, Aoki A, Asaeda Y, Ishida N, et al. Analysis of the long-term prognosis for conjunctival malignant melanomas in Japan. Nippon Ganka Gakkai Zasshi. 1999;103:449–55. (in Japanese).

PubMed  CAS  Google Scholar 

Kimura K, Usui Y, Goto H. Clinical findings and prognosis of 11 cases of conjunctival malignant melanoma. Nippon Ganka Gakkai Zasshi. 2012;116:503–9. (in Japanese).

PubMed  Google Scholar 

Goto H, Yamakawa N, Tsubota K, Umazume K, Usui Y, Mori H, et al. Clinical features and current treatment status of conjunctival melanoma. Nippon Ganka Gakkai Zasshi. 2023;127:7–18. (in Japanese).

Google Scholar 

Shields CL, Shields JA, Gündüz K, Cater J, Mercado GV, Gross N, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497–507.

Article  PubMed  CAS  Google Scholar 

Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78:252–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol. 2002;25:248–55.

Article  PubMed  Google Scholar 

Jain P, Finger PT, Damato B, Coupland SE, Heimann H, Kenawy N, et al. Multicenter, international assessment of the eighth edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma. JAMA Ophthalmol. 2019;137:905–11.

Article  PubMed  PubMed Central  Google Scholar 

Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthalmic Plast Reconstr Surg. 1998;14:208–15.

Article  PubMed  CAS  Google Scholar 

Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol. 1997;115:808–15.

Article  PubMed  CAS  Google Scholar 

Fujioka M, Sakamoto M, Azumi A, Kanomata N. A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta: efficacy and side effects. Nippon Ganka Gakkai Zasshi. 2006;110:51–7. (in Japanese).

PubMed  CAS  Google Scholar 

Paridaens AD, McCartney AC, Minassian DC, Hungerford JL. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994;78:520–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou C, Wang Y, Jia R, Fan X. Conjunctival melanoma in Chinese patients: local recurrence, metastasis, mortality, and comparisons with caucasian patients. Invest Ophthalmol Vis Sci. 2017;58:5452–9.

Article  PubMed  Google Scholar 

Shields CL, Kaliki S, Al-Dahmash SA, Lally SE, Shields JA. American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthalmic Plast Reconstr Surg. 2012;28:313–23.

Article  PubMed  Google Scholar 

Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2022;43:3399–408.

Google Scholar 

Satomi H, Wang B, Fujisawa H, Otsuka F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokine. 2002;18:108–15.

Article  PubMed  CAS  Google Scholar 

Ismail A, Yusuf N. Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract. 2014;2014:847545.

Article  PubMed  PubMed Central  Google Scholar 

Folberg R, McLean IW, Zimmerman IE. Malignant melanoma of the conjunctiva. Hum Pathol. 1985;16:136–43.

Article  PubMed  CAS  Google Scholar 

Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118:389–e95952.

Article  PubMed  Google Scholar 

Chen P-Y, Liao Y-L, Chu Y-C, Tsai Y-J. Conjunctival melanoma: a 20-year survey in a comprehensive medical center. J Formos Med Assoc. 2021;120:250–5.

Article  PubMed  Google Scholar 

Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.

Article  PubMed  CAS  Google Scholar 

Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828–36.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212–8.

Article  PubMed  CAS  Google Scholar 

Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. 2015;21:451–67.

Article  PubMed  CAS  Google Scholar 

Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74:615–9.

Article  PubMed  PubMed Central  CAS  Google Scholar